Moderate IV Sedation Simulation with iTIVA App

Klingler, Karl; Heard, Christopher

School of Dental Medicine, University at Buffalo, Buffalo, NY, USA



Introduction

There are many ways to accomplish Moderate Sedation. In our Pediatric Dental Residency Program, the use of Moderate IV Sedation is frequently used to help accomplish dental work for young children, that otherwise wouldn't be able to be completed due to poor behavior. Currently, we use a weight based algorithm where we use Midazolam, Fentanyl, (Figure 1) and Dexmedetomidine (Figure 2) in a specific order and timing to accomplish the desired sedation level.

The iTIVA® app plots Plasma and BioPhase levels for patients with different ages / weights and for different sedation agents. The iTIVA® app is an Anesthesia pharmacokinetic modeling app designed in Columbia, available for iPhone/iPad use. It can plot both Plasma and BioPhase drug levels for commonly used sedation agents.

The purpose of this study is to evaluate our Pediatric Moderate IV Sedation algorithm using the iTIVA® app. Our specific interest was evaluating if our algorithm allowed sufficient time for BioPhase levels (concentration of sedative agent at it's effect site) to peak prior to subsequent dosing.

Methods


We created three SIM groups based upon ages/weight as well as two known scenarios to evaluate our dosing algorithm. The majority of the SIM cases were Midazolam and Fentanyl with Dexmedetomidine added for certain indications. For each of these SIM-Patients the Plasma level and BioPhase level for the sedatives used were plotted on a time-based graph. The iTIVA® app did not have BioPhase plotting capability for pediatric Midazolam, however after contacting the App developer and submitting pharmacokinetic publications, he kindly added this to a beta test version for our research project. This modification update is now available for all app users.

Figure :

1	2021 MOD PED IV SEDATION DOSE REGIMEN, GUIDE AND DOSING ALGORITHM											
Т_		MIDAZOLAM 1 MG/ML, USUALLY 2 ML VIAL				FENTANYL 50 MCG/ML, USUALLY 2 ML VIAL				MID/FENT Dosing per KG		
		STARTING DOSING				ADDITIONAL DOSING		MAXIMUM DOSING		MAXIMUM DOSE/KG		
	WEIGHT	FIRST	SECOND	FIRST	SECOND	SUBSEQ.	SUBSEQ.	TOTAL	TOTAL	WEIGHT	MID	FENT
	(kg)	MID (mg)	MID (mg)	FENT (mcg)	FENT (mcg)	MID (mg)	FENT (mcg)	MID (mg)	FENT (mcg)	(kg)	(~mg/kg)	(~mcg/kg)
	15 to 20	1	1	12.5	12.5	0.5	12.5	5	50	15 to 20	0.33	3.3
	21 to 25	1	1	25	12.5	0.5	12.5	6	62.5	21 to 25	0.30	3.1
	26 to 30	1.5	1	25	25	0.5	12.5	7	75	26 to 30	0.27	2.9
	31 to 35	2	1	25	25	0.5 or 1	12.5	8	87.5	31 to 35	0.26	2.8
	36 to 40	2	1	50	25	0.5 or 1	12.5	8	100	36 to 40	0.22	2.8
	41 to 45	2	1.5	50	25	0.5 or 1	25	8	125	41 to 45	0.20	3.0
	46 to 50	2	2	50	25	1	25	9	150	46 to 50	0.20	3.3
	51 to 60	2	2	50	50	1	25	9	175	51 to 60	0.20	3.4
	60+	2	2	50	50	1 or 2	25	10	200	60+	0.16	3.3


SIM 1: 5 year old BMI 15

Midazolam 1st dose had peaked but second dose hadn't peaked completely prior to 3rd dose, Fentanyl dosing seems appropriate




SIM 2: 5 year old BMI 35

Midazolam dosing sequence is appropriate, Fentanyl 1st dose hadn't reached peak effect prior to second dose.




Results

Overall we created sedation SIM plots for 20 SIMpatients. Age groups were 5 years, 13 years and 18 years. BMI groups were 15, 20 or 25 and 35. Use of Dexmedetomidine early or late or as indicated. Examples are shown below (SIM 1 through 7).




SIM 4: 13 year old BMI 20

Midazolam the second dose is given prior to the first dose reaching peak effect,




SIM 5: 18 year old BMI 25


The third dose of Midazolam is given prior to the second dose reaching peak effect. Fentanyl dosing is appropriate.



SIM 6: Very Difficult to sedate 5 year old BMI 15


After maxing out on Midazolam and Fentanyl, Dexmedetomidine is used and provides a good long term sedation effect, note slow onset and delay to peak effect.





SIM 7: 13 year old BMI 15 Prolonged Case

During a long case all the Midazolam and Fentanyl medications were used,



Conclusions

With sedation, safety is of upmost importance. This study helped better evaluate our current Moderate IV Sedation protocol from a pharmacokinetic point of view. BioPhase levels do peak several minutes after peak IV levels, so an appropriate dosing interval is required. Older patients would appear to require a greater interval due to the slower Initial redistribution effect. After reviewing the different scenarios, the data suggests that our sedation protocol is appropriate and safe.



Special thanks to Dr. Ramirez- iTIVA Developer